The use of Pan-PPAR Agonists for Treatment of Tauopathies and Huntington’s disease Inventor: Flint Beal, MD Chairman of Neurology and Neuroscience/Neurologist-in-Chief.

Slides:

Advertisements

Similar presentations

Update in ILD: Current Approaches to IPF Andrew M. Tager, M.D.

Advertisements

The Drug Discovery Process

Parkinson’s disease (PD) is one of the most common chronic progressive neurodegenerative diseases. PD has a prevalence of 1.2 million people in Europe.

1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.

An thorough analysis of Tuxworth et al.’s 2011 article. EVIDENCE THAT MUTATIONS IN THE CLN3 GENE CAUSE FAILED OXIDATIVE STRESS RESPONSE AND CONTRIBUTE.

Optimization of Preclinical Animal Models Steven Perrin, PhD CEO, CSO ALS Therapy Development Institute.

This is only for personal educational purposes.

Functional autoradiography: Incorporation of [ 35 S]-GTP γ S In vitro target function [ 35 S]GTPγS X.

BioSciencs Foro November 8th, New York.

MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.

E2A and acute lymphoblastic leukemias (ALL). A closer look at the E2A gene... Other names: TCF3, ITF1, and Factors E12/E47 Located on chromosome 19 Encodes.

Chapter 18 Human Heredity by Michael Cummings ©2006 Brooks/Cole-Thomson Learning Chapter 18 Genetics of Behavior.

Retinoic Acid Receptor Alpha and Acute Promyelocytic Leukemia Nidhi Thapar April 1, 2004.

Gwenn Garden, M.D., Ph.D. Department of Neurology University of Washington.

AMPAKINE Compounds for the Treatment of Rett Syndrome

The National Association for Pancreatic Cancer Prese nts.

By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.

Clinical Trials Penny Hogarth, MD OHSU Department of Neurology April 6th, 2007.

Joellen Little-Kemper November 9, Introduction Imagine that the activation of a single gene could result in increased: *obesity resistance *insulin.

The Human Genome Project: prospects for cardiology Claude L’Enfant MD Director, National Heart, Lung, and Blood Institute National Institutes of Health,

TGF-β Receptor I/ALK5: An Attractive Therapeutic Target in Tumor Development By Jake Bridgers.

CHAPTER 23: Neurological Disorders in Women. Introduction Gender differences exist in the development and expression of several neurological disorders,

Effect of alternative metabolic fuels as a potential ALS therapy in mice and humans Csilla Ari, Craig R. Goldhagen, Angela Poff, Heather Held, Carol Landon,

Jessica L. Feig PhD1, Keith M. Giles PhD2, Iman Osman MD2, Andrew G

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

Oxidative Stress, Septic Shock, and Survival Matthew Greenwood April 29, 2015.

Parstatin: a novel pharmacological target for the development of new agents in the treatment of cardiovascular diseases Nikos E. Tsopanoglou Assistant.

Technology Available for Licensing US Army Medical Research and Materiel Command A Pharmaceutical Composition Containing pGLU- GLU-PRO-NH 2 and Methods.

SiRNA unrelated AdipoR1 AdipoR2 None Ad Osm A9 None Ad Osm A9 None Ad Osm A9 Ratio ** Protein (μM) None Ad Osm A siRNA Unrelated.

Dr. Sigal fleisher-Berkovich Neuroinflammation is regulated by angiotensin related drugs: possible implications for neurodegenerative diseases.

Humanized Mice in Dermatology Research Russell L. Griffin, BS, Thomas S. Kupper, MD, Sherrie J. Divito, MD, PhD Department of Dermatology, Brigham and.

Stratifying RTT Patients for Clinical Trials A Mutation Based Approach

Fibroblast growth factor receptor (FGFR) gene family aberrations in cholangiocarcinoma Katsuyuki Miyabe, MD, PhD Lewis R. Roberts, MB ChB, PhD.

Research Team of Elucidating Pathophysiology & Discovering Targets in Metabolic Disorders.

Synergic effect of exercise and nutrition intervention on disease model Wook Song, Ph.D. Health & Exercise Science Laboratory Institute of Sport Science.

Metabolic Syndrome: Focused on AMPK as Molecular Target for Metabolic Syndrome Bayu Lestari.

Role of heat shock proteins in aging

Phospho-mimic variant (T94E) of Tctex-1 Inventor: Ching-Hwa Sung, PhD Departments of Ophthalmology and Cell Biology Weill Cornell Medical College.

NCI Initiatives to Develop Non-Clinical Models for Pediatric Oncology Malcolm A. Smith, MD, PhD 17 March 2004.

Wang Chung Han. INTRODUCTION Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a CAG expansion in the huntingtin.

Abstract In response to numerous pathologic stimuli, the myocardium undergoes a hypertrophic response characterized by increased.

Resource Allocation in Translational Neuroscience Tom Insel, M.D. Director National Institute of Mental Health National Institutes of Health March 5, 2009.

UPDATE ON SCA RESEARCH George Wilmot, MD, PhD. DISCLAIMER  The information provided by speakers in any presentation made as part of the 2016 NAF Annual.

Reflections on animal models of neurological disorders Marie-Francoise Chesselet UCLA

ENDOCANNABINOID REGULATION OF ALTERNATIVE MICROGLIA ACTIVATION IN MULTIPLE SCLEROSIS CAITLIN JAGLA.

Neurophysiology Neuropsychiatric & Neurodegenerative disorders

Drug Discovery &Development

Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough? Tony Sourisseau, PhD, Khaled.

US Army Medical Research and Materiel Command

Nat. Rev. Neurol. doi: /nrneurol

Genetics and epigenetics of NAFLD and NASH

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

New class of anti-inflammatory agents for colonic epithelial cells

Drug Design and Drug Discovery

Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough? Tony Sourisseau, PhD, Khaled.

Kathleen M. Schoch, Timothy M. Miller Neuron

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

The PPAR-α agonist GW7647 reduces experimentally induced myopia.

Muscling In on PGC-1α for Improved Quality of Life in ALS

K-Means clustering of protein and mRNA expression patterns after PPAR agonists treatments. k-Means clustering of protein and mRNA expression patterns after.

Aaron Ritter MD Cleveland Clinic Lou Ruvo Center for Brain Health

Fig. 1. Bexarotene promotes PPARδ activation to ameliorate the neurotoxicity of mutant huntingtin. Bexarotene promotes PPARδ activation to ameliorate the.

Target disease and target populations for 21st century vaccine developmentIncluded in the list are the agents of infectious diseases for which vaccines.

Targets of thiazolidinedione (TZD) drugs in Alzheimer’s disease.

Schematic diagram that summarizes the findings of the current study showing that diabetes-induced peroxynitrite inactivates the NGF/TrkA receptor prosurvival.

Table 1. Bioactive properties in Coriolus versicolor

Apoptosis: Activate NF-κB or die?

-supported study By Dr. Chao Peng

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Presentation transcript:

The use of Pan-PPAR Agonists for Treatment of Tauopathies and Huntington’s disease Inventor: Flint Beal, MD Chairman of Neurology and Neuroscience/Neurologist-in-Chief New York Presbyterian Hospital-Weill Medical College of Cornell University

PPAR and neuroprotection Well established field – 92 hits on pubmed; 13 reviews Great review of pan-PPAR agonism by Beal, 2008 PPAR agonists are anti-inflammatory, antioxidant, protect mitochondria

“Modulation of several molecular and pathophysiological pathways simultaneously may be a better approach for neuroprotection. This could be achieved by using a combination of several pharmacological agents or, preferably, with only one having pleiotrophic effects. PPAR agonists have the ability to induce gene expression and modulate several molecular pathways at the level of transcription. Therefore, PPAR agonists or drugs acting on transcription factor receptors are possible therapeutic targets for neurodegenerative diseases. Further, additional experimental, preclinical and clinical studies are necessary using PPAR agonists to determine neuroprotective effects on disease progression as well as on disease onset.’

What’s new? Reduction to practice in P301S mice (tauopathy) Reduction to practice in HD mouse

Bezafibrate reduced tau pathology in P301S mice.

Bezafibrate rescued behavioral abnormalities in P301S mice

Bezafibrate restores the PGC-1α signaling pathway in R6/2 mice

Bezafibrate improves the behavioral phenotype and extends survival in R6/2 mice

Developmental status –POC established in 2 mouse models with bezafibrate Intellectual Property –Provisional application filed Publications –Johri A et al. (2012) Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet Mar 1;21(5): Hum Mol Genet Mar 1;21(5):

Contact: Bruce Toman, CLP Technology Commercialization and Liaison Officer CCTEC 418 E 71st Street, Suite 61 New York, NY ph: